TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2885928
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at night
Study: 25796150
Drug: Traditional Shangke
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Shangke Jiegu tablets
Study: 20739691
Drug: Joint mobilization
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint mobilization self‐exercise treatment
Study: 16701922
Drug: Enriched milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched milk (500 cm³ per day) with 5.7 g of oleic acid, 0.2 g of omega-3 fatty acid, 150 µg of folic acid, and 7.5 mg of vitamin E
Study: 12673463
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of pure natural honey (20 ml before, after, and 6 hours post-radiation therapy)
Study: 18485252
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of pure natural honey
Study: 2580172
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg) while fasting
Study: 2580172
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) after eating
Study: 2580172
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg twice a day for 3-12 months) taken 1 h before eating
Study: 2580172
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg twice a day for 3-12 months) taken during or immediately after eating
Study: 31775406
Drug: Local intradermal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intradermal BTX-A injection
Study: 26658447
Drug: Hyperglycemia (>140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (>140 mg/dL)
Study: 26658447
Drug: Normoglycemia (≤140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia (≤140 mg/dL)
Study: 26658447
Drug: Higher glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher glucose levels (per 10 mg/dL increase) in patients with incomplete reperfusion
Study: 9235005
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg atracurium
Study: 9235005
Drug: 0.0125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0125 mg/kg pancuronium followed by 0.45 mg/kg atracurium
Study: 27413070
Drug: Recombinant fusion
Normalized name: Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7
DrugBank: Verpasep caltespen (DB04959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant fusion protein ESAT6-CFP10 (1, 5, 10, or 20 μg/ml)
Study: 25715786
Drug: Continuous local
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous local anaesthetic infusion via wound infusion catheter (WIC)
Study: 23810678
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg/day)
Study: 6161689
Drug: SCAB chemotherapy
Normalized name: Scab-wort Root
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCAB chemotherapy (streptozocin, lomustine, doxorubicin hydrochloride, and bleomycin sulfate)
Study: 6161689
Drug: SCAB chemotherapy
Normalized name: Scab-wort Root
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCAB chemotherapy
Study: 28833562
Drug: ADS-5102 (amantadine)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADS-5102 (amantadine) 274 mg once daily at bedtime for 13 weeks
Study: 26237305
Drug: Water preloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water preloading (500 ml of water 30 min before meals)
Study: 23319439
Drug: 3,4-DHPAA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-DHPAA and EGCG (in vitro treatment)
Study: 21471566
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g in 500 ml of 0.9% saline intravenously over 4 h, n=16)
Study: 16424644
Drug: 6-week VACOP-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week VACOP-B followed by high-dose sequential chemotherapy (HDS) and autologous stem cell transplantation (ASCT)
Study: 11402280
Drug: NSAIDs and
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs and physical therapy
Study: 8565795
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with opioid receptor antagonists naltrexone and nalmefene
Study: 2233917
Drug: Corticosteroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (40 mg of prednisone twice daily)
Study: 31123852
Drug: Post-operative bladder
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative bladder instillation of chemotherapy
Study: 31123852
Drug: Platin-based chemotherapy
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platin-based chemotherapy for invasive UTUC
Study: 25224665
Drug: docetaxel-based chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel-based chemotherapy + zoledronic acid (ZA)
Study: 25224665
Drug: docetaxel-based chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel-based chemotherapy + placebo
Study: 17442125
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (CBT) for PTSD, conducted over a 5-week period (10 sessions)
Study: 17442125
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (CBT) for PTSD
Study: 16450851
Drug: New experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: New experimental treatment
Study: 8435991
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment given by community health centres (conventionally treated group)
Study: 28905166
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment including three motivational telephone interviews and a cognitive-behavioral self-help workbook
Study: 26555944
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m)
Study: 23893066
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) component of the depression prevention program 'Op Volle Kracht' (OVK), 8 lessons
Study: 23893066
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) component of OVK
Study: 20440520
Drug: Cyclo +
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclo + mtx (cyclosporin at 7.5 mg/kg/day for 6 weeks, then 4 mg/kg/day + methotrexate at 5 mg/kg/week for 1 year)
Study: 20440520
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard insulin therapy)
Study: 16249142
Drug: Narrowband blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband blue light treatment (8 sessions of 10- or 20-minute treatments over 4 weeks)
Study: 16249142
Drug: Narrowband blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband blue light treatment
Study: 1959800
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III concentrate administration during surgery
Study: 6115807
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg, taken twice a day
Study: 6115807
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken twice a day
Study: 28950351
Drug: CPB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB plus cixutumumab 6 mg/kg i.v. weekly
Study: 15717138
Drug: Acute TD-GTN
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute TD-GTN 20 mg
Study: 26055927
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin 125mg every 6 hours for 10 days
Study: 19239555
Drug: 0.75% adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% adenosine lotion
Study: 14585873
Drug: Individual dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dose of rFSH (100-250 IU/day)
Study: 14585873
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of rFSH (150 IU/day)
Study: 2857910
Drug: Povidone-iodine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 2% (50 ml instilled before catheter removal)
Study: 30805708
Drug: Cement augmentation
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cement augmentation of PHILOS screws (augmented group)
Study: 30805708
Drug: PHILOS screws
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PHILOS screws without cement augmentation (control group)
Study: 16087956
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (induction CT with cisplatin 120 mg/m2 on days 1, 29, and 57; vinorelbine 30 mg/m2/wk from day 1 to day 78; followed by thoracic RT at 66 Gy in 33 fractions)
Study: 16087956
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (RT started on day 1 with two cycles of cisplatin 20 mg/m2/d and etoposide 50 mg/m2/d; consolidation therapy with cisplatin 80 mg/m2 on days 78 and 106; vinorelbine 30 mg/m2/wk from days 78 to 127)
Study: 19910828
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no treatment applied)
Study: 15329509
Drug: Pravastatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10-20 mg) plus diet
Study: 9283055
Drug: Estradiol valeranate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valeranate 10 mg (E)
Study: 9283055
Drug: Estradiol valeranate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valeranate 4 mg plus prasterone enantate 200 mg (E+P)
Study: 8510192
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (nicotine gum)
Study: 3305207
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance chemotherapy for 2 years (Group A)
Study: 3305207
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance chemotherapy plus viral oncolysate injection on day 15 (Group A+IT)
Study: 3305207
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy after early consolidation
Study: 23650800
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) intervention applied to bilateral Xuehai (SP 10), Zusanli (ST36), Taichong (LR3), and Sanyinjiao (SP 6) for 30 min, once daily for 15 days.
Study: 23650800
Drug: Intensive endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive endurance exercise (Harvard step test) for 30 min, once daily for 15 days.
Study: 21091250
Drug: Lactotripeptides (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactotripeptides (3 mg of Ile‐Pro‐Pro/Val‐Pro‐Pro)
Study: 18209670
Drug: OTZ (oxothiazolidine‐4‐carboxylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTZ (oxothiazolidine‐4‐carboxylic acid) 210 mg/kg per day every 8 hrs for 14 days
Study: 16599263
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 5 g daily for 6 weeks)
Study: 15128893
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin (100 mg/m² IV on days 1, 22, and 43) plus radiotherapy (60 to 66 Gy in 30 to 33 fractions over 6 to 6.6 weeks)
Study: 15128893
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin plus radiotherapy
Study: 8065733
Drug: Intraligamentary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injection of slow-release methylprednisolone (Depomedrol)
Study: 3418088
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) enemas (2 g in 100 ml)
Study: 3418088
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) suppositories (1 g b.i.d.)
Study: 30902603
Drug: Cylindrical implants
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implants
Study: 28557376
Drug: Both tapered
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both tapered and cylindrical implants
Study: 9438598
Drug: 40-Gy radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-Gy radiotherapy and 4 weeks 5-FU treatment
Study: 7512469
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240mg daily
Study: 7512469
Drug: Enalapril 20mg
Normalized name: enalapril 20 MG
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 20mg daily
Study: 7512469
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Verapamil + Enalapril or Hydrochlorothiazide)
Study: 3520382
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) - 20 consecutive daily treatments of 100% O2 followed by 7 booster treatments over 6 months
Study: 29568976
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone 0.8 mg
Study: 29568976
Drug: Intramuscular naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular naloxone 0.8 mg
Study: 21756847
Drug: PegIFNα2a 180
Normalized name: peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PegIFNα2a 180 μg/wk plus daily Rbv 800-1200 mg
Study: 21756847
Drug: PegIFNα2b 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα2b 1.5 μg/kg/week plus daily Rbv 800-1200 mg
Study: 20735515
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 500 mg of azithromycin per day (3 days)
Study: 12830040
Drug: Intermittent hyperkalemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent hyperkalemic cold blood cardioplegia and topical cardiac cooling (Control)
Study: 10806608
Drug: tolbutamide 500
Normalized name: tolbutamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolbutamide 500 mg plus tolcapone 200 mg
Study: 10806608
Drug: tolbutamide 500
Normalized name: tolbutamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolbutamide 500 mg plus placebo
Study: 29504812
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec FlexTouch®
Study: 26843473
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release hGH (SR-hGH) 2-mg injections weekly for 3 months
Study: 21126667
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (10 mg)
Study: 21126667
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (10 mg) with morphine (100 mcg)
Study: 21126667
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine (10 mg)
Study: 21126667
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine (10 mg) with morphine (100 mcg)
Study: 9202548
Drug: Patient-Controlled Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Analgesia (PCA) with intravenous alfentanil, mean dose 1.03 mg
Study: 9202548
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with intravenous pethidine, mean dose 62.5 mg
Study: 1527232
Drug: Carbamazepine and
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine and valproic acid combination
Study: 30457892
Drug: Turmeric-containing herbal
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric-containing herbal combination tablets
Study: 30470580
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg BID
Study: 24989666
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg TID
Study: 20826249
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cells (BMCs) - 100 million intracoronary BMCs administered 3 to 10 days post-procedure
Study: 15781538
Drug: hyperbaric intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hyperbaric intrathecal solution of 10 mg bupivacaine
Study: 15781538
Drug: isobaric intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isobaric intrathecal solution of 10 mg bupivacaine
Study: 15781538
Drug: hypobaric intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hypobaric intrathecal solution of 10 mg bupivacaine
Study: 12552188
Drug: EDTA-containing propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA-containing propofol (ECP) 2 mg/kg
Study: 12552188
Drug: Sulfite-containing propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfite-containing propofol (SCP) 2 mg/kg
Study: 10826131
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cyanamide
Study: 10826131
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cyanamide at 0.3 mg/kg
Study: 10826131
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cyanamide at 1.0 mg/kg
Study: 10826131
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of cyanamide at 1.5 mg/kg
Study: 6984828
Drug: BCG vaccine,
Normalized name: BCG vaccine, live INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine, administered as a series of four weekly intradermal injections.
Study: 31782747
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of care
Study: 31782747
Drug: BMI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMI and insulin levels correlation
Study: 27486985
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Cb with SIT
Study: 25280441
Drug: GNB3 C825T
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNB3 C825T polymorphism homozygous CC group
Study: 14566442
Drug: Deramciclane (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane (60 mg for 8 days)
Study: 10991864
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg of VGC per os (p.o.) once a day (q.d.)
Study: 10991864
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of VGC p.o. q.d.
Study: 10991864
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral GCV three times a day
Study: 10991864
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of intravenous (i.v.) GCV per kg of body weight q.d.
Study: 9236310
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral ritodrine from the 25th to the end of the 37th week of gestation
Study: 1358620
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 g.kg‐1)
Study: 30817250
Drug: FOLFIRINOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX plus Pegylated Recombinant Human Hyaluronidase (PEGPH20) at a dosage of 3 µg/kg every 2 weeks
Study: 21774293
Drug: Telephone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based intervention (TBI) with motivational interviewing and supportive techniques, individual weekly therapy sessions of 20 to 30 minutes via telephone for six weeks.
Study: 19547854
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy in the postoperative recovery room and subsequently in the infirmary
Study: 19547854
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy in the infirmary exclusively
Study: 16752186
Drug: Adiponectin concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin concentrations in the third trimester (9.9+/‐1.4 microg/ml) compared to pregravid condition (13.5+/‐1.8 microg/ml)
Study: 16752186
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion in pregravid women